With a market valuation of ₹509.10 Cr, Zim Laboratories Ltd. is a small capitalization company active in the pharmaceutical industry. The company is involved in the development, production and delivery of specific generic pharmaceutical products in solid oral doses in addition to providing finished formulations (FF) and pre-formulation intermediates (PFI) for a number of major therapeutic categories. . The company released its second quarter results along with a 2:1 free share issue.
The company said in a filing today that its board had considered and approved “the increase in the authorized share capital of the company by Rs. 25,00,00,000/- (rupees twenty-five crores only ) divided into 2,50,00,000 (two crores and fifty lakhs only) equity shares of ₹10/- (10 rupees only) each at Rs. 75,00,00,000/- (rupees seventy-five crores only) divided into 7,50,00,000 (seven crores fifty lakhs only) shares of Rs. 10/- (ten rupees only) each consequential amendment to Article V of the Company’s Memorandum of Association, subject to shareholder approval at the general meeting; and issuance of free shares in the proportion of 2 (TWO) participating shares of ₹10/- each for every 1 (ONE) existing capital share of ₹10/- each held by the Shareholders of the Company on the date of record, subject to the approval of the Shareholders in General Meeting and to the statutory/regulatory approvals, other approvals, consents, authorizations, if necessary.”
Zim Laboratories bonus stock details as per available exchange data
Total number of securities proposed for issuance or total amount for which securities will be issued (approximately): 3,24,83,876 equity shares of Rs. 10 each.
Whether the bonus comes from free reserves created from profits or from a share premium account: The free shares would be issued from the Securities Premium Account available on March 31, 2022.
Bonus rate: 2:1 i.e., 2 (two) shares of capital of 10 rupees each for 1 (one) fully paid up share of capital of 10 rupees each
Share capital paid up before the bonus issue: Rs. 16,24,19,380 divided into 1,62,41,938 equity shares of Rs. 10 each.
Share capital released after the bonus issue: Rs. 48,72,58,140 divided into 4,87,25,814 equity shares of Rs. 10 each.
Free reserves and/or issue premium required for the implementation of the bonus issue: An amount of Rs. 32,48,38,760 would be capitalized from the Securities Premium account for the issuance of free shares.
Estimated date on which these free shares would be credited/sent: Subject to obtaining shareholder approval and statutory/regulatory approvals, other approvals, if required, free shares will be credited/sent within 2 months from the date of Board approval, c i.e. no later than January 11, 2023.
On an individual basis, the company reported net sales of ₹99.26 Cr at T2FY23 compared to ₹75.72 Cr posted in Q2FY22, representing a year-on-year growth of 31.08%. The company reported net income of ₹100.70 Cr during the quarter ended September 2022 compared to ₹76.61 Cr posted in the same quarter last year, representing a year-on-year growth of 31.44%. The company declared a total expenditure of ₹92.54 Cr at T2FY23 compared to ₹73.68 Cr in Q2FY22, representing a year-on-year jump of 25.59%. The company reported profit before tax (PBT) of ₹8.15 Cr at T2FY23 compared to ₹2.92 Cr in Q2FY22, representing a year-over-year gain of 179.10%. The company reported net income of ₹5.65 Cr at T2FY23 compared to ₹2 Cr posted in Q2FY22, representing an annual growth of 182.50%. The EPS is fitted to ₹3.49 per share in Q2FY23 versus ₹3.47 at T1FY23 and ₹1.24 at T2FY22.
On a consolidated basis, the company reported net sales of ₹99.40 Cr at T2FY23 compared to ₹77.47 Cr posted in Q2FY22, representing a year-on-year growth of 28.30%. The company reported total revenue of ₹100.82 Cr compared to ₹78.34 Cr posted in Q2FY22, representing a year-on-year growth of 28.69%. The company declared a total expenditure of ₹92.86 Cr at T2FY23 compared to ₹74.14 Cr posted in Q2FY22, representing a year-over-year gain of 25.24%. The company declared a PBT of ₹7.95 Cr at T2FY23 compared to ₹4.20 Cr posted in Q2FY22, representing a year-on-year gain of 89.28%. The company reported net income of ₹5.44 Cr at T2FY23 compared to ₹3.25 Cr posted in Q2FY22, representing a year-on-year growth of 67.38%. The EPS is fitted to ₹3.35 per share at Q2FY23 versus ₹3.17 at T1FY23 and ₹2 at T2AF22.
Shares of Zim Laboratories Ltd closed Friday at ₹313.50 each, up 0.064% from the previous close of ₹313.30. The stock has produced a multibagger return of 146.40% over the past five years and a multibagger return of 282.49% over the past three years. The stock has generated a multibagger return of 150.90% over the past year, and so far in 2022 it has produced a multibagger return of 163.56% on a YTD basis.
Catch all the trade news, market news, breaking events and the latest updates on Live Mint. Download the Mint News app to get daily market updates.
More less
